Egetis in the media

Redeye research, April 30, 2020

Egetis: Aladote upside

World of Gastrointestinal Oncology, Feb 17 2020

Neuropathy experienced by colorectal cancer patients receiving oxaliplatin

Interview with Mr Akschuti, analyst at Pareto Securities, Feb 6 2020

Pareto Securities equity analyst elaborates on the US clinical hold for the POLAR-M study.

Läkemedelsvärlden, December 14, 2020 (in Swedish)

Increasing number of cases with acetaminophen overdose in Sweden.

The independent financial news site EFN, Dec 9 2019

Egetis mentioned on EFN as one of the Swedish healthcare companies to keep an eye on. The discussion in English starts 5 min 30 sec into the program.

Liver Research

“Thus, if efficacy in high overdose patients can be established, calmangafodipir may be a promising complementary antidote to NAC.” Oct 2019

Jaeschke H, Duan L, Nguyen N, Ramachandran A, Mitochondrial damage and biogenesis in acetaminophen-induced liver injury, Liver Research

Svd Näringsliv 19 januari 2019 (in Swedish)

Egetis: Håller nerverna i styr genom studietider
Keeps their nerves in control through the study